10-Q: Dynatronics Reports Lower Sales and Gross Profit in Second Quarter of Fiscal Year 2024

Dynatronics Corporation experienced a significant decrease in net sales and gross profit for the quarter ended December 31, 2023, compared to the same period in the previous year.

Summary

• Dynatronics Corporation reported a net sales decrease of 25.1% to $8.15 million for the quarter ended December 31, 2023, compared to $10.88 million in the same quarter of 2022.
• The company's gross profit also decreased by 40.6% to $1.82 million, representing 22.3% of net sales, down from 28.1% in the prior year's quarter.
• Selling, general, and administrative expenses decreased by 29.5% to $2.72 million for the quarter.
• The net loss for the quarter was $1.01 million, compared to a net loss of $841,000 in the same quarter of the previous year.
• For the six months ended December 31, 2023, net sales decreased by 23.7% to $17.50 million, and gross profit decreased by 38.5% to $4.13 million.
• The net loss for the six-month period was $1.34 million, nearly the same as the $1.35 million loss in the prior year's comparable period.
• The company has a line of credit with a maximum availability of $7.5 million, with $1.897 million drawn as of December 31, 2023.
• A reverse stock split at a ratio of 1-for-5 was completed on February 1, 2023.
• Shareholders approved a resolution granting the board the authority to effect a reverse stock split at any whole number between one-for-five to one-for-ten within one year from December 7, 2023.

Sentiment

Score: 3

Explanation: The document indicates a negative sentiment due to significant decreases in sales and gross profit, coupled with a net loss. While cost-cutting measures are in place, the overall financial performance is concerning.

Positives

• Selling, general, and administrative expenses decreased by $1.14 million for the quarter and $2.713 million for the six months ended December 31, 2023.
• The company has a line of credit available for operating capital.
• Inventories decreased by $650,000, indicating improved inventory management.

Negatives

• Net sales decreased by 25.1% for the quarter and 23.7% for the six months ended December 31, 2023.
• Gross profit decreased by 40.6% for the quarter and 38.5% for the six months ended December 31, 2023.
• The company experienced a net loss of $1.01 million for the quarter and $1.34 million for the six months ended December 31, 2023.
• The decrease in sales is attributed to a competitor acquisition, reduced OEM volume, and lower demand for orthopedic soft bracing products.

Risks

• The company faces uncertainties in the broader economic environment affecting the global supply chain.
• Higher personnel costs could negatively impact the company's financial performance.
• Changes to customer or product mix could have an adverse effect on the company's liquidity and cash.
• The company may need to raise additional funds through the sale of equity or debt securities or from credit facilities.
• The company's ability to realize deferred income tax assets is uncertain.

Future Outlook

The company believes that its cash generated from operations, current capital resources, and proceeds of equity sales, if any, will provide sufficient liquidity to fund operations for the next 12 months, but there is no assurance that additional funds may not be required.

Management Comments

• Management is taking steps to adjust inventory management in response to the uncertain operating environment.
• Management continues to evaluate and take action, as necessary, to preserve adequate liquidity and ensure that the business can continue to operate during these uncertain times.

Industry Context

The decrease in sales may reflect broader challenges in the medical device industry, including supply chain disruptions and changing customer demand. The acquisition of a competitor by a key customer highlights the competitive landscape and potential for consolidation in the rehabilitation product sector.

Comparison to Industry Standards

• The company's gross profit margin of 22.3% for the quarter is below the typical range for medical device companies, which often aim for margins above 40%.
• Companies like Stryker and Medtronic, which are larger and more diversified, typically report higher gross profit margins due to economies of scale and a broader product portfolio.
• Smaller companies in the medical device sector, such as those focused on specific niches, may experience more volatility in sales and margins, making Dynatronics' results somewhat comparable to other small-cap medical device companies.
• The company's reliance on a line of credit for operating capital is not uncommon for smaller companies, but it also indicates a need for careful cash management and potential risks associated with debt financing.

Related Party Transactions

• The company leases facilities from shareholders and entities controlled by shareholders, with expenses totaling $332,989 for the three months and $666,938 for the six months ended December 31, 2023.

Stakeholder Impact

• Shareholders may be concerned about the decrease in sales and profitability.
• Employees may be affected by cost-cutting measures.
• Customers may experience changes in product availability or pricing.
• Suppliers may be impacted by changes in inventory management and purchasing decisions.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to evaluate and take action to preserve adequate liquidity.
• The company may consider further adjustments to inventory management.
• The company may need to raise additional funds through the sale of equity or debt securities.

Key Dates

Keywords

medical devices, physical therapy, rehabilitation, orthopedics, pain management, athletic training, net sales, gross profit, operating loss, reverse stock split, line of credit, financial results